PNPLA3 gene in liver diseases

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 399-412

  Trépo, Eric ^a,b,c   Romeo, Stefano ^d,e,f   Zucman Rossi, Jessica ^a,g,h   Nahon, Pierre ^a,h,i  

^a INSERM   (France)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITÉ PARIS 13   (France)

ⁱ HÔPITAL JEAN VERDIER   (France)

Author keywords

Fibrosis; Genetic association studies; Hepatocellular carcinoma; Heritability; Steatosis; Triglycerides

Indexed keywords

PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 PROTEIN; PHOSPHOLIPASE; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ALCOHOL LIVER DISEASE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL PRACTICE; DISEASE ASSOCIATION; FATTY LIVER; GENETIC ASSOCIATION STUDY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; GENOME-WIDE ASSOCIATION STUDY;

GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPASE; LIVER DISEASES; MEMBRANE PROTEINS;

EID: 84973894670     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.03.011     Document Type: Review

References (130)

1. [1] Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. [2] Visscher, P.M., Hill, W.G., Wray, N.R., Heritability in the genomics era–concepts and misconceptions. Nat Rev Genet 9 (2008), 255–266.
3. [3] T.J. Polderman, B. Benyamin, de Leeuw, C.A., Sullivan, P.F., van Bochoven, A., Visscher, P.M., et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat Genet 47 (2015), 702–709.
4. [4] Karlsen, T.H., Melum, E., Franke, A., The utility of genome-wide association studies in hepatology. Hepatology 51 (2010), 1833–1842.
5. [5] D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, Shianna, K.V., Urban, T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009), 399–401.
6. [6] S. Romeo, J. Kozlitina, Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
7. [7] Yuan, X., Waterworth, D., Perry, J.R., Lim, N., Song, K., Chambers, J.C., et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 83 (2008), 520–528.
8. [8] Kollerits, B., Coassin, S., Kiechl, S., Hunt, S.C., Paulweber, B., Willeit, J., et al. A common variant in the adiponutrin gene influences liver enzyme values. J Med Genet 47 (2010), 116–119.
9. [9] J.C. Chambers, W. Zhang, J. Sehmi, X. Li, M.N. Wass, P. Van der Harst, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 43 (2011), 1131–1138.
10. [10] A. Kotronen, L.E. Johansson, Johansson, L.M., Roos, C., Westerbacka, J., Hamsten, A., et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52 (2009), 1056–1060.
11. [11] Sookoian, S., Castano, G.O., Burgueno, A.L., Fernandez Gianotti, T., Rosselli, M.S., Pirola, C.J., A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 50 (2009), 2111–2116.
12. [12] Valenti, L., Al-Serri, A., Daly, A.K., Galmozzi, E., Rametta, R., Dongiovanni, P., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1209–1217.
13. [13] Speliotes, E.K., Butler, J.L., Palmer, C.D., Voight, B.F., Hirschhorn, J.N., PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52 (2010), 904–912.
14. [14] Y. Rotman, C. Koh, Zmuda, J.M., Kleiner, D.E., Liang, T.J., The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52 (2010), 894–903.
15. [15] Sookoian, S., Pirola, C.J., Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53 (2011), 1883–1894.
16. [16] Singal, A.G., Manjunath, H., Yopp, A.C., Beg, M.S., Marrero, J.A., Gopal, P., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 109 (2014), 325–334.
17. [17] Shen, J.H., Li, Y.L., Li, D., Wang, N.N., Jing, L., Huang, Y.H., The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid Res 56 (2015), 167–175.
18. [18] L. Zhang, W. You, Zhang, H., Peng, R., Zhu, Q., Yao, A., et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol 30 (2015), 821–829.
19. [19] Xu, R., Tao, A., Zhang, S., Deng, Y., Chen, G., Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep, 5, 2015, 9284.
20. [20] C.N. Palmer, C. Maglio, Pirazzi, C., Burza, M.A., Adiels, M., Burch, L., et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One, 7, 2012, e39362.
21. [21] Stojkovic, I.A., Ericson, U., Rukh, G., Riddestrale, M., Romeo, S., Orho-Melander, M., The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes Nutr, 9, 2014, 388.
22. [22] C.S. Tang, H. Zhang, C.Y. Cheung, M. Xu, Ho, J.C., Zhou, W., et al. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nat Commun, 6, 2015, 10206.
23. [23] E.K. Speliotes, L.M. Yerges-Armstrong, J. Wu, R. Hernaez, L.J. Kim, Palmer, C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet, 7, 2011, e1001324.
24. [24] Donati, B., Motta, B.M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., et al. The rs2294918 E434K variant modulates PNPLA3 expression and liver damage. Hepatology 63 (2016), 787–798.
25. [25] Tian, C., Stokowski, R.P., Kershenobich, D., Ballinger, D.G., Hinds, D.A., Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42 (2010), 21–23.
26. [26] F. Stickel, S. Buch, Lau, K., zu Schwabedissen, H.M., Berg, T., Ridinger, M., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53 (2011), 86–95.
27. [27] Trépo, E., Gustot, T., Degre, D., Lemmers, A., Verset, L., Demetter, P., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 55 (2011), 906–912.
28. [28] Chamorro, A.J., Torres, J.L., Miron-Canelo, J.A., Gonzalez-Sarmiento, R., Laso, F.J., Marcos, M., Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Aliment Pharmacol Ther 40 (2014), 571–581.
29. [29] Salameh, H., Raff, E., Erwin, A., Seth, D., Nischalke, H.D., Falleti, E., et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol 110 (2015), 846–856.
30. [30] S. Buch, F. Stickel, E. Trépo, Way, M., Herrmann, A., Nischalke, H.D., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47 (2015), 1443–1448.
31. [31] Friedrich, K., Wannhoff, A., Kattner, S., Brune, M., Hov, J.R., Weiss, K.H., et al. PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. J Gastroenterol Hepatol 29 (2014), 1477–1484.
32. [32] Valenti, L., Rumi, M., Galmozzi, E., Aghemo, A., Del Menico, B., De Nicola, S., et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53 (2011), 791–799.
33. [33] Cai, T., Dufour, J.F., Muellhaupt, B., Gerlach, T., Heim, M., Moradpour, D., et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 55 (2011), 529–535.
34. [34] Muller, T., Buch, S., Berg, T., Hampe, J., Stickel, F., Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 55 (2011), 732–733.
35. [35] Trépo, E., Pradat, P., Potthoff, A., Momozawa, Y., Quertinmont, E., Gustot, T., et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54 (2011), 60–69.
36. [36] J.H. Fan, M.Q. Xiang, Li, Q.L., Shi, H.T., Guo, J.J., PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: a meta-analysis. Gut Liver, 2015, 10.5009/gnl15261.
37. [37] S. De Nicola, P. Dongiovanni, Aghemo, A., Cheroni, C., D'Ambrosio, R., Pedrazzini, M., et al. Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. PLoS One, 9, 2014, e106022.
38. [38] Milano, M., Aghemo, A., Mancina, R.M., Fischer, J., Dongiovanni, P., De Nicola, S., et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 62 (2015), 111–117.
39. [39] Scheiner, B., Mandorfer, M., Schwabl, P., Payer, B.A., Bucsics, T., Bota, S., et al. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One, 10, 2015, e0143429.
40. [40] M. Vigano, L. Valenti, Lampertico, P., Facchetti, F., Motta, B.M., D'Ambrosio, R., et al. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 58 (2013), 1245–1252.
41. [41] Brouwer, W.P., van der Meer, A.J., Boonstra, A., Pas, S.D., de Knegt, R.J., de Man, R.A., et al. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver Int 35 (2015), 438–447.
42. [42] Zampino, R., Coppola, N., Cirillo, G., Boemio, A., Grandone, A., Stanzione, M., et al. Patatin-like phospholipase domain-containing 3 I148M variant is associated with liver steatosis and fat distribution in chronic hepatitis B. Dig Dis Sci 60 (2015), 3005–3010.
43. [43] Q. Pan, R.N. Zhang, Y.Q. Wang, R.D. Zheng, Y.Q. Mi, Liu, W.B., et al. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol 21 (2015), 8605–8614.
44. [44] J. Tong, J. Guo, Hu, J., Hou, S., Zhang, Y., Li, Q., Correlation between patatin-like phospholipase domain-containing protein 3 gene polymorphisms and liver cirrhosis in a Chinese han population with chronic hepatitis B. Hepat Mon, 14, 2014, e18943.
45. [45] Sookoian, S., Pirola, C.J., PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ: the liver. Hepatology 59 (2014), 2068–2071.
46. [46] K. Friedrich, C. Rupp, Hov, J.R., Steinebrunner, N., Weiss, K.H., Stiehl, A., et al. A frequent PNPLA3 variant is a sex specific disease modifier in PSC patients with bile duct stenosis. PLoS One, 8, 2013, e58734.
47. [47] Valenti, L., Maggioni, P., Piperno, A., Rametta, R., Pelucchi, S., Mariani, R., et al. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol 18 (2012), 2813–2820.
48. [48] F. Stickel, S. Buch, Zoller, H., Hultcrantz, R., Gallati, S., Osterreicher, C., et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet 23 (2014), 3883–3890.
49. [49] Stattermayer, A.F., Traussnigg, S., Dienes, H.P., Aigner, E., Stauber, R., Lackner, K., et al. Hepatic steatosis in Wilson disease–Role of copper and PNPLA3 mutations. J Hepatol 63 (2015), 156–163.
50. [50] Morse, C.G., McLaughlin, M., Matthews, L., Proschan, M., Thomas, F., Gharib, A.M., et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis 60 (2015), 1569–1578.
51. [51] Price, J.C., Seaberg, E.C., Latanich, R., Budoff, M.J., Kingsley, L.A., Palella, F.J. Jr, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 109 (2014), 695–704.
52. [52] R.M. Mancina, R. Spagnuolo, Milano, M., Brogneri, S., Morrone, A., Cosco, C., et al. PNPLA3 148M carriers with inflammatory bowel diseases have higher susceptibility to hepatic steatosis and higher liver enzymes. Inflamm Bowel Dis 22 (2016), 134–140.
53. [53] Trépo, E., Nahon, P., Bontempi, G., Valenti, L., Falleti, E., Nischalke, H.D., et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 59 (2014), 2170–2177.
54. [54] Takeuchi, Y., Ikeda, F., Moritou, Y., Hagihara, H., Yasunaka, T., Kuwaki, K., et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 48 (2013), 405–412.
55. [55] Falleti, E., Fabris, C., Cmet, S., Cussigh, A., Bitetto, D., Fontanini, E., et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 31 (2011), 1137–1143.
56. [56] H.D. Nischalke, C. Berger, Luda, C., Berg, T., Muller, T., Grunhage, F., et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One, 6, 2011, e27087.
57. [57] Trépo, E., Guyot, E., Ganne-Carrie, N., Degre, D., Gustot, T., Franchimont, D., et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 55 (2012), 1307–1308.
58. [58] Guyot, E., Sutton, A., Rufat, P., Laguillier, C., Mansouri, A., Moreau, R., et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 58 (2013), 312–318.
59. [59] M.A. Burza, C. Pirazzi, Maglio, C., Sjoholm, K., Mancina, R.M., Svensson, P.A., et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis 44 (2012), 1037–1041.
60. [60] Liu, Y.L., Patman, G.L., Leathart, J.B., Piguet, A.C., Burt, A.D., Dufour, J.F., et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61 (2014), 75–81.
61. [61] Corradini, S.G., Burza, M.A., Molinaro, A., Romeo, S., Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology, 53, 2011, 1776 [Author reply 1777].
62. [62] Ali, M., Yopp, A., Gopal, P., Beg, M.S., Zhu, H., Lee, W., et al. A variant in PNPLA3 associated with fibrosis progression but not hepatocellular carcinoma in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 14 (2016), 295–300.
63. [63] Charni, F., Sutton, A., Rufat, P., Laguillier, C., Mansouri, A., Moreau, R., et al. Chemokine rantes promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis. Cancer Epidemiol Biomarkers Prev 20 (2011), 1439–1446.
64. [64] Tarhuni, A., Guyot, E., Rufat, P., Sutton, A., Bourcier, V., Grando, V., et al. Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 61 (2014), 342–350.
65. [65] Nahon, P., Sutton, A., Rufat, P., Charnaux, N., Mansouri, A., Moreau, R., et al. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis. J Hepatol 56 (2011), 426–432.
66. [66] Nahon, P., Sutton, A., Rufat, P., Ziol, M., Akouche, H., Laguillier, C., et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 50 (2009), 1484–1493.
67. [67] Nahon, P., Sutton, A., Rufat, P., Ziol, M., Thabut, G., Schischmanoff, P.O., et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134 (2008), 102–110.
68. [68] A. Sutton, P. Nahon, Pessayre, D., Rufat, P., Poire, A., Ziol, M., et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 66 (2006), 2844–2852.
69. [69] Nault, J.C., Nahon, P., Genetic predisposition to hepatocellular carcinoma in alcoholic cirrhosis: the NCAN-PNPLA3-lipid connection?. J Hepatol 61 (2014), 971–972.
70. [70] J. Kozlitina, E. Smagris, Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjaerg-Hansen, A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
71. [71] Falleti, E., Cussigh, A., Cmet, S., Fabris, C., Toniutto, P., PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis 48 (2016), 69–75.
72. [72] C. Pirazzi, L. Valenti, B.M. Motta, Pingitore, P., Hedfalk, K., Mancina, R.M., et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 23 (2014), 4077–4085.
73. [73] Huang, Y., He, S., Li, J.Z., Seo, Y.K., Osborne, T.F., Cohen, J.C., et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 107 (2010), 7892–7897.
74. [74] Dubuquoy, C., Robichon, C., Lasnier, F., Langlois, C., Dugail, I., Foufelle, F., et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol 55 (2011), 145–153.
75. [75] Kershaw, E.E., Hamm, J.K., Verhagen, L.A., Peroni, O., Katic, M., Flier, J.S., Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 55 (2006), 148–157.
76. [76] He, S., McPhaul, C., Li, J.Z., Garuti, R., Kinch, L., Grishin, N.V., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285 (2010), 6706–6715.
77. [77] Chamoun, Z., Vacca, F., Parton, R.G., Gruenberg, J., PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell 105 (2013), 219–233.
78. [78] Huang, Y., Cohen, J.C., Hobbs, H.H., Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 286 (2011), 37085–37093.
79. [79] Jenkins, C.M., Mancuso, D.J., Yan, W., Sims, H.F., Gibson, B., Gross, R.W., Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 279 (2004), 48968–48975.
80. [80] Lake, A.C., Sun, Y., Li, J.L., Kim, J.E., Johnson, J.W., Li, D., et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res 46 (2005), 2477–2487.
81. [81] Li, J.Z., Huang, Y., Karaman, R., Ivanova, P.T., Brown, H.A., Roddy, T., et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 122 (2012), 4130–4144.
82. [82] P. Pingitore, C. Pirazzi, Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 1841 (2014), 574–580.
83. [83] Chen, W., Chang, B., Li, L., Chan, L., Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52 (2010), 1134–1142.
84. [84] Basantani, M.K., Sitnick, M.T., Cai, L., Brenner, D.S., Gardner, N.P., Li, J.Z., et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res 52 (2011), 318–329.
85. [85] Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K.M., Gromada, J., et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61 (2015), 108–118.
86. [86] C. Pirazzi, M. Adiels, Burza, M.A., Mancina, R.M., Levin, M., Stahlman, M., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57 (2012), 1276–1282.
87. [87] Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Parks, E.J., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 (2014), 726–735.
88. [88] R.M. Mancina, N. Matikainen, Maglio, C., Soderlund, S., Lundbom, N., Hakkarainen, A., et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J Clin Endocrinol Metab 100 (2015), E821–E825.
89. [89] A. Mondul, R.M. Mancina, A. Merlo, Dongiovanni, P., Rametta, R., Montalcini, T., et al. PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity. J Nutr 145 (2015), 1687–1691.
90. [90] Kovarova, M., Konigsrainer, I., Konigsrainer, A., Machicao, F., Haring, H.U., Schleicher, E., et al. The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans. J Clin Endocrinol Metab 100 (2015), E1568–E1574.
91. [91] Hernandez-Gea, V., Friedman, S.L., Pathogenesis of liver fibrosis. Annu Rev Pathol 6 (2011), 425–456.
92. [92] Nkontchou, G., Bastard, J.P., Ziol, M., Aout, M., Cosson, E., Ganne-Carrie, N., et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 53 (2011), 827–833.
93. [93] Fields, A.L., Soprano, D.R., Soprano, K.J., Retinoids in biological control and cancer. J Cell Biochem 102 (2007), 886–898.
94. [94] Muto, Y., Moriwaki, H., Saito, A., Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340 (1999), 1046–1047.
95. [95] Min, H.K., Sookoian, S., Pirola, C.J., Cheng, J., Mirshahi, F., Sanyal, A.J., Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 307 (2014), G66–G76.
96. [96] Koppenol, W.H., Bounds, P.L., Dang, C.V., Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11 (2011), 325–337.
97. [97] Sookoian, S., Castano, G.O., Pirola, C.J., PNPLA3 I148M variant is associated with metabolic stress-response phenotype in patients with nonalcoholic fatty liver disease. Hepatology, 61, 2015, 1769.
98. [98] S. Sookoian, C.J. Pirola, PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol 18 (2012), 6018–6026.
99. [99] Loomba, R., Quehenberger, O., Armando, A., Dennis, E.A., Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 56 (2015), 185–192.
100. [100] R.M. Mancina, P. Dongiovanni, Petta, S., Pingitore, P., Meroni, M., Rametta, R., et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology, 2016, 10.1053/j.gastro.2016.01.032.
101. [101] Hunter, D.J., Gene-environment interactions in human diseases. Nat Rev Genet 6 (2005), 287–298.
102. [102] Scorletti, E., West, A.L., Bhatia, L., Hoile, S.P., McCormick, K.G., Burdge, G.C., et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 63 (2015), 1476–1483.
103. [103] V. Nobili, D. Liccardo, Bedogni, G., Salvatori, G., Gnani, D., Bersani, I., et al. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr, 9, 2014, 392.
104. [104] Dongiovanni, P., Romeo, S., Valenti, L., Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 20 (2014), 12945–12955.
105. [105] Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42 (2014), D1001–D1006.
106. [106] Lander, E.S., The new genomics: global views of biology. Science 274 (1996), 536–539.
107. [107] Gibson, G., Rare and common variants: twenty arguments. Nat Rev Genet 13 (2011), 135–145.
108. [108] Genomes Project Consortium, Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
109. [109] Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., et al. Finding the missing heritability of complex diseases. Nature 461 (2009), 747–753.
110. [110] L. Jostins, S. Ripke, Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
111. [111] Brant, S.R., Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 17 (2011), 1–5.
112. [112] Boomsma, D., Busjahn, A., Peltonen, L., Classical twin studies and beyond. Nat Rev Genet 3 (2002), 872–882.
113. [113] Loomba, R., Schork, N., Chen, C.H., Bettencourt, R., Bhatt, A., Ang, B., et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149 (2015), 1784–1793.
114. [114] Witte, J.S., Visscher, P.M., Wray, N.R., The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 15 (2014), 765–776.
115. [115] Cirulli, E.T., Goldstein, D.B., Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11 (2010), 415–425.
116. [116] McClellan, J., King, M.C., Genetic heterogeneity in human disease. Cell 141 (2010), 210–217.
117. [117] M.R. Nelson, D. Wegmann, Ehm, M.G., Kessner, D., St Jean, P., Verzilli, C., et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337 (2012), 100–104.
118. [118] Kraft, P., Wacholder, S., Cornelis, M.C., Hu, F.B., Hayes, R.B., Thomas, G., et al. Beyond odds ratios–communicating disease risk based on genetic profiles. Nat Rev Genet 10 (2009), 264–269.
119. [119] Jakobsdottir, J., Gorin, M.B., Conley, Y.P., Ferrell, R.E., Weeks, D.E., Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet, 5, 2009, e1000337.
120. [120] Manolio, T.A., Bringing genome-wide association findings into clinical use. Nat Rev Genet 14 (2013), 549–558.
121. [121] Nahon, P., Zucman-Rossi, J., Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol 57 (2012), 663–674.
122. [122] Manolio, T.A., Bailey-Wilson, J.E., Collins, F.S., Genes, environment and the value of prospective cohort studies. Nat Rev Genet 7 (2006), 812–820.
123. [123] Meigs, J.B., Shrader, P., Sullivan, L.M., McAteer, J.B., Fox, C.S., Dupuis, J., et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359 (2008), 2208–2219.
124. [124] S. Kathiresan, O. Melander, Anevski, D., Guiducci, C., Burtt, N.P., Roos, C., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008), 1240–1249.
125. [125] Manolio, T.A., Genomewide association studies and assessment of the risk of disease. N Engl J Med 363 (2010), 166–176.
126. [126] Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science 332 (2011), 1519–1523.
127. [127] T.H. Karlsen, F. Lammert, R.J. Thompson, Genetics of liver disease: From pathophysiology to clinical practice. J Hepatol 62 (2015), S6–S14.
128. [128] J.A. Tennessen, A.W. Bigham, T.D. O'Connor, Fu, W., Kenny, E.E., Gravel, S., et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337 (2012), 64–69.
129. [129] L.G. Fritsche, W. Igl, J.N. Bailey, F. Grassmann, S. Sengupta, Bragg-Gresham, J.L., et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48 (2016), 134–143.
130. [130] H.D. Nischalke, P. Lutz, Kramer, B., Sohne, J., Muller, T., Rosendahl, J., et al. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. J Hepatol 61 (2014), 1073–1079.